Driving business performance through partnering, networking and in-depth discussion.

Seven years after its inception the European Union (EU) regulation on Orphan Medicinal Products has yielded over 500 orphan designations leading to some 45 orphan drugs been approved for marketing in the EU. Of these 500 over 60% were developed by leading companies or institutions based in Europe.

Previous survey showed that corporations were asking for a BD focused meeting packed with networking opportunities, to make sure you meet with the key figures in the orphan drug space. That is why we have invited over 150 patient organisations from Europe to join allowing you to network with patient groups and identify the best partner for you portfolio.

The 3rd Annual Orphan Drug Summit will bring together a great cocktail of industry leaders from pharma/biotech companies, patient advocacy groups, government, regulators, investors and insurance companies to shares approaches, challenges and successes in orphan drug development.

With the support of Genetic Alliance UK.




Contact and registration


You can Get the best rates by booking now to ensure your place at this unique meeting – Book online or call +1 212 537 5898. If you want to share, make suggestions, send an abstract: [email protected]